%0 Journal Article
%T What¡¯s new in the treatment of advanced small-cell lung cancer
%A Hao-Ran Zhai
%A Jia-Tao Zhang
%A Wen-Zhao Zhong
%A Yi-Long Wu
%A Zhong-Yi Dong
%J SCIE-indexed Journal
%D 2017
%R 10.21037/13854
%X Although the incidence of lung cancer has been declining since 2000, it has remained the leading cause of cancer-related mortality worldwide for the last 10 years for both sexes (1,2). Small-cell lung cancer (SCLC), which accounts for approximately 15% of lung cancers, continues to have a dismal prognosis due to its aggressive biological characteristics, with an overall 5-year survival rate of less than 10% (3). SCLC is highly sensitive to initial chemotherapy; however, nearly all patients eventually relapse. The only FDA-approved treatment for relapsed SCLC in the past 2 decades has been single-agent topotecan, but it has a poor response rate (7%), and its survival rate is unacceptable (4,5)
%U http://tcr.amegroups.com/article/view/13854/html